Učitavanje...
Novel therapeutics in multiple myeloma
Most myeloma patients still experience recurrent relapse and eventually become resistant and/or intolerant of effective agents such as corticosteroids, alkylating agents, immune modulators (lenalidomide and thalidomide) or proteasome inhibitors such as bortezomib. Once this happens average survivals...
Spremljeno u:
| Glavni autor: | |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2012
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3905954/ https://ncbi.nlm.nih.gov/pubmed/22507794 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1179/102453312X13336169156131 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|